Communiqués DiaMedica Therapeutics Inc.

Actions

DMAC

CA25253X2077

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/07/2026			Varia. 5j.	Varia. 1 janv.
7,300 ^USD	+2,38%		-4,82%	-8,29%

23/06	DiaMedica Therapeutics administre les premières doses à des patientes dans un essai de phase 2 de DM199 pour le traitement du retard de croissance fœtale	CI
23/06	DiaMedica Therapeutics administre les premières doses à des patients dans un essai de phase 2 sur le retard de croissance fœtale	MT

Communiqués

17/07	DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
23/06	DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction	BU
16/06	DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program	BU
27/05	DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026	BU
20/05	DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial	BU
12/05	DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference	BU
06/05	DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights	BU
30/04	DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026	BU
07/04	RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms	AQ
30/03	DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights	BU
23/03	DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026	BU
05/03	DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia	BU
24/02	DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences	BU
19/01	DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
16/01	DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
18/12	DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA	BU
12/11	DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights	BU
10/11	DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London	BU
06/11	DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025	BU
29/09/25	DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)	BU
08/09/25	DiaMedica Therapeutics to Participate in Upcoming Investor Conferences	AQ
05/09/25	DiaMedica Therapeutics to Participate in Upcoming Investor Conferences	BU
02/09/25	DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference	BU
12/08/25	DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights	BU
06/08/25	DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer	BU